Bill · HR
H.R. 3162 (119th)
Affordable and Safe Prescription Drug Importation Act of 2025
Original
Introduced
1 May 2025
Last action
1 May 2025 · Introduced
Status
Referred to the House Committee on Energy and Commerce.
Sponsors
Janice Schakowsky, Steve Cohen, Lloyd Doggett, Ilhan Omar, Chellie Pingree, Mark Pocan, Yassamin Ansari, Del. Norton, Eleanor Holmes [D-DC-At Large], Greg Casar
Subjects
Healthcare, European Union
Source updated
4 August 2026
Summary
Affordable and Safe Prescription Drug Importation Act of 2025 This bill expands the categories of prescription drugs that may be imported into the United States and the countries from which such drugs may be imported. Current law allows the Department of Health and Human Services (HHS) to authorize importation of certain eligible prescription drugs from Canada if HHS certifies that doing so would pose no additional risk to public health and safety, among other requirements. HHS long declined to make the requisite certification, citing safety concerns (e.g., contamination, counterfeiting), but ultimately made the certification in 2020 and has since approved one state plan to import drugs. The bill removes the certification requirement and requires HHS to issue regulations that permit importation of qualifying prescription drugs from the United Kingdom, Switzerland, and member states of the European Union, in addition to Canada. After one year, if HHS determines that importation of drugs from these countries has been conducted safely, HHS may authorize importation from other countries that meet certain requirements. The bill also expands the types of prescription drugs eligible for importation to include, for example, biologics such as insulin. Further, the bill allows individuals to use an eligible licensed foreign pharmacy to fill a U.S.-issued prescription for a qualifying drug for personal use. Currently, an individual seeking to import a prescription drug generally must acquire a waiver from HHS. Finally, the bill imposes criminal penalties for websites that sell counterfeit drugs or dispense drugs without a required prescription.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
1 May 2025
Introduced
Referred to the House Committee on Energy and Commerce.
Source: IntroReferral
1 May 2025
Introduced
Introduced in House
Source: IntroReferral
1 May 2025
Introduced
Introduced in House
Source: IntroReferral
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
2 official files
Introduced in House
Introduced in House · EN · 1 May 2025
Introduced in House
summary · EN · 1 May 2025
Sponsors
- Janice Schakowsky · D · Sponsor
- Steve Cohen · D · Sponsor
- Lloyd Doggett · D · Sponsor
- Ilhan Omar · D · Sponsor
- Chellie Pingree · D · Sponsor
- Mark Pocan · D · Sponsor
- Yassamin Ansari · D · Cosponsor
- Del. Norton, Eleanor Holmes [D-DC-At Large] · D · Cosponsor
- Greg Casar · D · Cosponsor
- · hsif00 · Standing
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/119th-congress/house-bill/3162
- Open data entity: https://api.congress.gov/v3/bill/119/hr/3162
- us · 119-hr-3162 · source updated 4 August 2026